BBI

NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New Geographic Markets Will Severely Impair its Earnings Potential Identifies at Least Ten Other Areas of Misperception That Suggest Floor & Decor's Challenges Are Structural and Are Not Cyclical or Easily Fixed Provides Evidence That Floor & Decor Recently Made Revisions to Key Revenue Claims, Numerous Omissions of Past Disclosures, Changes to Accounting Policy Language and Modifications to Business Practices That Obscure its Growing Challenges Provides Evidence That CEO Thom

10-Q - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it has initiated the multiple ascending dose ("MAD") portion of the ongoing Phase 1 clinical trial

EFFECT - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

According to data from Benzinga Pro, during Q2, Brickell Biotech's (NASDAQ:BBI) reported sales totaled $4.32 million. Despite a 87.81% increase in earnings, the company posted a loss of $1.15 million. In Q1, Brickell Biotech brought in $92 thousand in sales but lost $9.41 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Bricke

New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX's novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company"). The new name, logo, website, and brand

DEL AM - Brickell Biotech, Inc. (0000819050) (Filer)

S-1 - Brickell Biotech, Inc. (0000819050) (Filer)

https://twitter.com/PatentGrants/status/1565734028765892610   https://patentcenter.uspto.gov/applications/17105376/ifw/docs

- Reuters

10-Q/A - Brickell Biotech, Inc. (0000819050) (Filer)

8-K - Brickell Biotech, Inc. (0000819050) (Filer)

8-K - Brickell Biotech, Inc. (0000819050) (Filer)

10-Q - Brickell Biotech, Inc. (0000819050) (Filer)

Brickell Biotech (NASDAQ:BBI) reported quarterly losses of $(0.01) per share. This is a 93.75 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $4.32 million which beat the analyst consensus estimate of $3.13 million by 37.86 percent. This is a 2.76K percent increase over sales of $151.00 thousand the same period last year.

8-K - Brickell Biotech, Inc. (0000819050) (Filer)

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second qua

  Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE:DDL) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ:EVLO) is projected to report earnings for its second quarter. • Affimed (NASDAQ:AFMD) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE:CORR) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE:SIX) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ:WFCF) is projected to report earn

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ:MOHO) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ:KSPN) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ:HSCS) jumped 89.6% to close at $3.28. Poseida Therapeutics

BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights. To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conferenc

8-K - Brickell Biotech, Inc. (0000819050) (Filer)